Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
BioAtla (NASDAQ: BCAB) reported Q2 2024 financial results and clinical progress. Key highlights include:
1. Ozuriftamab vedotin granted Fast Track Designation by FDA for head and neck cancer; FDA meeting anticipated in 2H 2024.
2. Evalstotug showed low incidence of immune-related adverse events; Phase 2 combination study with pembrolizumab on track for initial data in 2H 2024.
3. Mecbotamab vedotin Phase 2 trial in NSCLC showed improved overall survival in patients with KRAS mutations.
4. Cash balance projected to fund operations through Q3 2025.
5. Q2 2024 financial results: R&D expenses $16.2M (down from $31.0M in Q2 2023), G&A expenses $5.8M, net loss $21.1M, cash and equivalents $61.7M as of June 30, 2024.
BioAtla (NASDAQ: BCAB) ha riportato i risultati finanziari e i progressi clinici del secondo trimestre 2024. I punti salienti includono:
1. Ozuriftamab vedotin ha ricevuto la Designazione Fast Track dalla FDA per il cancro della testa e del collo; si prevede un incontro con la FDA nella seconda metà del 2024.
2. Evalstotug ha mostrato una bassa incidenza di eventi avversi immunologici; lo studio di combinazione di Fase 2 con pembrolizumab è in programma per fornire i dati iniziali nella seconda metà del 2024.
3. La sperimentazione di Fase 2 di Mecbotamab vedotin nel carcinoma polmonare non a piccole cellule ha mostrato un miglioramento della sopravvivenza globale nei pazienti con mutazioni KRAS.
4. Si prevede che il saldo di cassa finanzi il funzionamento fino al terzo trimestre del 2025.
5. Risultati finanziari del secondo trimestre 2024: spese per R&D 16,2 milioni di dollari (in calo dai 31,0 milioni di dollari nel secondo trimestre 2023), spese generali e amministrative 5,8 milioni di dollari, perdita netta 21,1 milioni di dollari, cassa e equivalenti 61,7 milioni di dollari al 30 giugno 2024.
BioAtla (NASDAQ: BCAB) informó sobre los resultados financieros y el progreso clínico del segundo trimestre de 2024. Los aspectos destacados incluyen:
1. Ozuriftamab vedotin recibió la Designación Fast Track de la FDA para el cáncer de cabeza y cuello; se anticipa una reunión con la FDA en la segunda mitad de 2024.
2. Evalstotug mostró una baja incidencia de eventos adversos relacionados con el sistema inmunológico; el estudio de combinación de Fase 2 con pembrolizumab está programado para proporcionar datos iniciales en la segunda mitad de 2024.
3. El ensayo de Fase 2 de Mecbotamab vedotin en NSCLC mostró una mejoría en la supervivencia global en pacientes con mutaciones KRAS.
4. Se proyecta que el saldo de efectivo financie las operaciones hasta el tercer trimestre de 2025.
5. Resultados financieros del segundo trimestre de 2024: gastos en I+D 16,2 millones de dólares (una disminución desde 31,0 millones en el segundo trimestre de 2023), gastos de G&A 5,8 millones, pérdida neta 21,1 millones, efectivo y equivalentes 61,7 millones al 30 de junio de 2024.
BioAtla (NASDAQ: BCAB)는 2024년 2분기 재무 결과 및 임상 진행 상황을 보고했습니다. 주요 내용은 다음과 같습니다:
1. Ozuriftamab vedotin이 FDA로부터 두경부암에 대한 패스트 트랙 지정서를 받았습니다. 2024년 하반기 FDA 회의가 예상됩니다.
2. Evalstotug는 면역 관련 부작용의 발생이 낮은 것으로 나타났습니다. pembrolizumab과의 2상 병용 연구는 2024년 하반기에 초도 데이터를 제공할 예정입니다.
3. Mecbotamab vedotin의 비소세포폐암(NSCLC) 2상 시험에서 KRAS 변이가 있는 환자의 전체 생존율이 개선되었습니다.
4. 현금 잔고는 2025년 3분기까지 운영 자금을 지원할 것으로 예상됩니다.
5. 2024년 2분기 재무 결과: 연구개발 비용 1,620만 달러(2023년 2분기 3,100만 달러에서 감소), 일반 및 관리 비용 580만 달러, 순손실 2,110만 달러, 2024년 6월 30일 기준 현금 및 현금성 자산 6,170만 달러.
BioAtla (NASDAQ: BCAB) a annoncé les résultats financiers et les progrès cliniques du deuxième trimestre 2024. Les points clés incluent :
1. Ozuriftamab vedotin a reçu la désignation Fast Track de la FDA pour le cancer de la tête et du cou ; une réunion avec la FDA est attendue dans la seconde moitié de 2024.
2. Evalstotug a montré une faible incidence d'événements indésirables liés au système immunitaire ; l'étude de combinaison de phase 2 avec pembrolizumab est sur la bonne voie pour des données initiales dans la seconde moitié de 2024.
3. L'essai de phase 2 de Mecbotamab vedotin dans le NSCLC a montré une amélioration de la survie globale chez les patients présentant des mutations KRAS.
4. Le solde de trésorerie devrait financer les opérations jusqu'au troisième trimestre 2025.
5. Résultats financiers du deuxième trimestre 2024 : dépenses R&D 16,2 millions de dollars (en baisse par rapport à 31,0 millions de dollars au deuxième trimestre 2023), dépenses générales et administratives 5,8 millions de dollars, perte nette 21,1 millions de dollars, liquidités et équivalents 61,7 millions de dollars au 30 juin 2024.
BioAtla (NASDAQ: BCAB) hat die finanziellen Ergebnisse und klinischen Fortschritte für das zweite Quartal 2024 veröffentlicht. Die wichtigsten Punkte sind:
1. Ozuriftamab vedotin erhielt von der FDA die Fast Track-Einstufung für Kopf- und Halskrebs; ein Treffen mit der FDA wird in der zweiten Hälfte von 2024 erwartet.
2. Evalstotug zeigte eine geringe Inzidenz von immunbedingten unerwünschten Ereignissen; die Phase-2-Kombinationsstudie mit Pembrolizumab befindet sich auf Kurs für erste Daten in der zweiten Hälfte von 2024.
3. Die Phase-2-Studie zu Mecbotamab vedotin in NSCLC zeigte eine verbesserte Gesamtüberlebensrate bei Patienten mit KRAS-Mutationen.
4. Der Cash-Bestand wird voraussichtlich die Betriebe bis zum dritten Quartal 2025 finanzieren.
5. Finanzielle Ergebnisse für das zweite Quartal 2024: F&E-Ausgaben 16,2 Millionen Dollar (rückläufig von 31,0 Millionen Dollar im zweiten Quartal 2023), allgemeine und Verwaltungskosten 5,8 Millionen Dollar, Nettoverlust 21,1 Millionen Dollar, Bargeld und Äquivalente 61,7 Millionen Dollar zum 30. Juni 2024.
- Ozuriftamab vedotin granted Fast Track Designation by FDA for head and neck cancer
- Evalstotug demonstrated low incidence and severity of immune-related adverse events in Phase 1 and 2 studies
- Mecbotamab vedotin showed trend for improved overall survival in NSCLC patients with KRAS mutations
- Current cash balance projected to fund operations through Q3 2025
- R&D expenses decreased by $14.8M compared to Q2 2023
- Net loss of $21.1M for Q2 2024
- Cash and cash equivalents decreased to $61.7M from $111.5M as of December 31, 2023
Insights
BioAtla's Q2 2024 results show a significant reduction in R&D expenses to
The reduced cash burn rate of
BioAtla's clinical progress is noteworthy across multiple programs. The Fast Track Designation for ozuriftamab vedotin in SCCHN is a significant regulatory milestone, potentially accelerating its development. The evalstotug (CAB-CTLA-4) data showing a low incidence of immune-related adverse events is promising, as it could differentiate this asset from existing CTLA-4 inhibitors like ipilimumab.
The mecbotamab vedotin results in NSCLC patients with KRAS mutations are intriguing, particularly the trend towards improved overall survival. This could be a valuable niche in a difficult-to-treat patient population. The ongoing trials, including the combination study of evalstotug with pembrolizumab, could provide important data for BioAtla's pipeline valuation. Investors should watch for upcoming data presentations at ESMO, SMR and SITC conferences, which could be significant catalysts.
BioAtla's Conditionally Active Biologic (CAB) platform is showing promise across multiple solid tumor indications. The Fast Track Designation for ozuriftamab vedotin and the potentially best-in-class safety profile of evalstotug are key differentiators in the competitive oncology landscape. The company's focus on KRAS-mutated NSCLC with mecbotamab vedotin could tap into a significant market opportunity.
The company's strategic positioning for FDA meetings and potential registrational trials by year-end is important for long-term value creation. The mention of advancing discussions with potential strategic partners suggests possible collaboration or licensing deals on the horizon. However, investors should be aware that while the current cash runway extends to Q3 2025, additional financing may be needed to fully capitalize on the clinical progress, especially if moving towards registrational trials.
- Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024
- Evalstotug (CAB-CTLA-4 antibody) demonstrated a similar low incidence and severity of immune-related adverse events across both Phase 1 and 2 studies; Phase 2 combination with pembrolizumab study continues to enroll and on track for initial data readout in 2H 2024
- Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 trial in NSCLC showed trend for improved overall survival among treated patients with tumors expressing mutated KRAS variants compared to KRAS wildtype; anti-tumor activity across multiple KRAS mutation variants including G12A, G12C, and G12V
- Current cash balance projected to fund operations through Q3 2025 sufficient to deliver clinical readouts in multiple indications, position our programs for one or more potentially registrational trials, and enhance our position in advancing strategic collaboration discussions
- Management to host conference call and webcast today at 4:30 PM Eastern Time
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and provided highlights on its clinical programs.
“BioAtla continues to execute across our CAB portfolio, highlighted by ongoing positive clinical responses and a potentially differentiated safety profile observed with our CAB Phase 2 assets,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “We are pleased to receive Fast Track Designation for ozuriftamab vedotin in the treatment of recurrent or metastatic head and neck cancer and are on track to meet with the FDA this year. The clinical profile of evalstotug, in particular the low incidence and severity of immune-related AEs, supports a potentially best-in-class CTLA-4 antibody for the treatment of multiple solid tumors. Further, we are encouraged with the emerging clinical profile of mecbotamab vedotin in patients with NSCLC harboring KRAS mutation variants. The company remains well-positioned for multiple FDA meetings by year end to discuss potentially registrational trials while we continue to advance discussions with potential strategic partners.”
Key Developments, Operational Updates and Upcoming Milestones
- Phase 2 Trials of ozuriftamab vedotin, CAB-ROR2-ADC in treatment-refractory SCCHN (NCT05271604) (median 3 prior lines of treatment)
- In the 29 evaluable patients to date, a total of 11 responses at the combined 2Q3W and Q2W dose regimens
- Fast Track Designation granted by FDA
- Data to be presented at upcoming poster presentation at ESMO in September
- In the 29 evaluable patients to date, a total of 11 responses at the combined 2Q3W and Q2W dose regimens
- Phase 1/2 dose-escalation trial of evalstotug, CAB-CTLA-4 (NCT05180799) across multiple solid tumor types (median 3 prior lines of treatment)
- Phase 1 dose-escalation study evaluated evalstotug in combination with nivolumab in patients who experienced failure of prior PD1 treatment
- Confirmed responses (3/8) with evalstotug (350 mg) in combination with PD-1
- Patients treated with ≥350mg evalstotug received more doses (mean, 7.2) compared with reported ipilimumab (3.4) or tremelimumab (4.3); no dose reductions occured
- Multiple patients on therapy without progression for >1 year
- Initial Phase 2 monotherapy data readout with two scans in treatment-refractory solid tumors at 350 mg (n=17) or 700 mg (n=2) (5 or 10 mg/kg for 70 kg person, respectively) to evaluate safety and immune-related adverse events
- Study ongoing
- Across 14 different tumor types, 10 patients with stable disease following monotherapy treatment; multiple patients experienced prolonged PFS (>10 months) to date
- Combined Phase 1 and Phase 2 safety (n=40) demonstrated low rate of grade 3 immune-related adverse events (irAEs) (4/40); no related grade 4 or 5 events; incidence and severity of irAEs consistent across Phase 1 and Phase 2 studies
- Data to be presented as oral presentation at the Society for Melanoma Research Congress in October and a poster presentation at the Society for Immunotherapy of Cancer in November
- Phase 2 first-line melanoma and first-line NSCLC patients at 700 mg (10 mg/kg for 70 kg person) in combination with pembrolizumab and in combination with pembrolizumab plus chemotherapy continues to enroll; on track for initial melanoma data readout in 2H 2024
- Phase 1 dose-escalation study evaluated evalstotug in combination with nivolumab in patients who experienced failure of prior PD1 treatment
- Phase 2 trial of mecbotamab vedotin, CAB-AXL-ADC (NCT04681131) in NSCLC (median 3 prior lines of treatment)
- Additional expansion cohort (n=33) 2Q3W evaluating AXL expression, dose, subtype and safety
- Subgroup results:
- AXL expression ≥
1% correlated with anti-tumor activity in both Q2W and 2Q3W dosing regimens - Anti-tumor activity with multiple confirmed responses among patients with tumors expressing mutated KRAS:
- Overall survival benefit trend observed among treated patients whose tumors express mutated KRAS compared to those with wildtype KRAS genotype
- Responses observed across patients with tumors expressing multiple KRAS mutation variants to date, including G12A, G12C, and G12V
- Response observed in a patient whose tumor expressed a mutated KRAS G12C variant who had experienced prior failure of sotorasib
- One patient treated in combination with PD-1 antibody remains in complete response for greater than 2 years
- mKRAS variants represent
30% of all NSCLC patients and is highly correlated with AXL expression
- AXL expression ≥
- Manageable safety continues with no new safety signals identified
- Phase 1/2 dose-escalation for CAB-EpCAM x CAB-CD3 TCE (BA3182, NCT05808634)
- Study is progressing and ongoing; on track for data readout of Phase 1 study in 2H 2024
Second Quarter 2024 Financial Results
Research and development expenses were
General and administrative expenses were
Net loss for the quarter ended June 30, 2024 was
Net cash used in operating activities for the six months ended June 30, 2024 was
Cash and cash equivalents as of June 30, 2024 were
Second Quarter 2024 Conference Call and Webcast Details
The management of BioAtla, Inc. will host a conference call and webcast for the investment community today, August 8, 2024, at 4:30 pm Eastern Time. A live webcast may be accessed here:
https://viavid.webcasts.com/starthere.jsp?ei=1677714&tp_key=f44f1624a8. The conference call can be accessed by dialing toll-free (800) 579-2543 (domestic) or (785) 424-1789 (international). The passcode for the conference call is BIOATLA.
A replay of the webcast and slides with topline interim clinical data referenced on the call will be available through “Events & Presentations” in the Investors section of the company’s website after the conclusion of the presentation and will be archived on the BioAtla website for one year.
About Ozuriftamab Vedotin (BA3021)
Ozuriftamab vedotin, CAB-ROR2-ADC, is a conditionally and reversibly active antibody drug conjugate directed against ROR2, a transmembrane receptor tyrosine kinase that is present across many different solid tumors including head and neck, lung, TNBC and melanoma. Overexpression of ROR2, a noncanonical wnt5A signaling receptor, forms a cancer axis that is associated with poor prognosis and resistance to chemo- and immunotherapies. This Phase 2 stage clinical asset is targeting multiple solid tumor indications, including the treatment of SCCHN patients who have previously progressed on PD-1/L1 therapies with or without platinum chemotherapy.
About Evalstotug (BA3071)
Evalstotug, is a CAB anti-CTLA-4 antibody that is being developed as an immuno-oncology agent with the goal of delivering efficacy at least comparable to the approved anti-CTLA-4 antibodies, but with lower toxicities due to the CAB's tumor microenvironment-restricted activity. This may enable safer anti-CTLA-4 antibody combination therapies, such as with anti-PD-1 antibody checkpoint inhibitors, and potentially broaden the patient population tolerant to combination therapy and deliver greater efficacy. Like our other CAB candidates, this Phase 2 clinical asset is designed to be conditionally and reversibly active in the tumor microenvironment. Evalstotug is being developed as a potential therapeutic for multiple solid tumor indications that are known to be responsive to CTLA-4 treatment in combination with a PD-1 blocking agent.
About Mecbotamab Vedotin (BA3011)
Mecbotamab vedotin, CAB-AXL-ADC, is a conditionally and reversibly active antibody drug conjugate targeting the receptor tyrosine kinase AXL. This Phase 2 stage clinical asset is targeting multiple solid tumor indications, including the treatment of soft tissue and bone sarcoma and non-small cell lung cancer (NSCLC) patients who have previously progressed on PD-1/L1, EGFR or ALK inhibitor therapies. The Office of Orphan Products Development (OOPD) at FDA granted Orphan Drug Designation to mecbotamab vedotin for the treatment of soft tissue sarcoma.
About CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager Antibody (BA3182)
BioAtla is developing BA3182 as a potential anticancer therapy for patients with advanced adenocarcinoma. BA3182 is a (CAB) EpCAM x (CAB) CD3 bispecific T cell engager antibody that contains two binding sites for EpCAM and two binding sites for CD3ε. The binding sites for EpCAM and CD3ε have been designed to bind their respective targets specifically and reversibly under the conditions found in the tumor microenvironment (TME) and to have reduced binding outside of the TME. The CAB selective binding to both the CAB EpCAM and CAB CD3ε arms are required to activate the T cell engagement against the tumor, thus enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla continues to advance the ongoing Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of BA3182 in advanced adenocarcinoma patients.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. BioAtla has an FDA-cleared IND for its next-gen CAB-Nectin4-ADC, BA3361, the Company’s first glycoconjugate. To learn more about BioAtla, Inc. visit www.bioatla.com.
Forward-looking statements
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words. Examples of forward-looking statements include, among others, statements we make regarding BioAtla’s business plans and prospects and whether its clinical trials will support registration; achievement of milestones; results, conduct, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in its clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions; the potential regulatory approval path for its product candidates; expectations about the sufficiency of its cash and cash equivalents to fund operations and expectations regarding R&D expenses and cash burn. Forward-looking statements are based on BioAtla's current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: potential delays in clinical and pre-clinical trials; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; our dependence on the success of our CAB technology platform; our ability to enroll patients in our ongoing and future clinical trials; the successful selection and prioritization of assets to focus development on selected product candidates and indications; our ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships; our reliance on third parties for the manufacture and supply of our product candidates for clinical trials; our reliance on third parties to conduct our clinical trials and some aspects of our research and preclinical testing; potential adverse impacts due to any resurgence of COVID-19 and its variants; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 26, 2024, in our Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024, and August 8, 2024 and our other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and BioAtla undertakes no duty to update such information except as required under applicable law.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
| BioAtla, Inc. Unaudited Condensed Statements of Operations and Comprehensive Loss (in thousands) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development expense | $ | 16,198 | $ | 30,960 | $ | 35,050 | $ | 52,657 | ||||||||
| General and administrative expense | 5,774 | 6,241 | 11,379 | 13,474 | ||||||||||||
| Total operating expenses | 21,972 | 37,201 | 46,429 | 66,131 | ||||||||||||
| Loss from operations | (21,972 | ) | (37,201 | ) | (46,429 | ) | (66,131 | ) | ||||||||
| Other income: | ||||||||||||||||
| Interest income | 900 | 1,460 | 2,123 | 2,940 | ||||||||||||
| Other expense | — | (11 | ) | — | (21 | ) | ||||||||||
| Total other income | 900 | 1,449 | 2,123 | 2,919 | ||||||||||||
| Net loss and comprehensive loss | $ | (21,072 | ) | $ | (35,752 | ) | $ | (44,306 | ) | $ | (63,212 | ) | ||||
| Net loss per common share, basic and diluted | (0.44 | ) | (0.75 | ) | (0.92 | ) | (1.33 | ) | ||||||||
| Weighted-average shares of common stock outstanding, basic and diluted | 48,214,893 | 47,706,426 | 48,151,176 | 47,639,977 | ||||||||||||
| BioAtla, Inc. Condensed Consolidated Balance Sheets Data (in thousands) | |||||||
| June 30, 2024 | December 31, 2023 | ||||||
| (unaudited) | |||||||
| Cash and cash equivalents | $ | 61,662 | $ | 111,471 | |||
| Total assets | 68,638 | 119,658 | |||||
| Total current liabilities | 17,462 | 28,344 | |||||
| Total liabilities | 37,268 | 48,986 | |||||
| Total stockholders’ equity | 31,370 | 70,672 | |||||
| Total liabilities and stockholders’ equity | 68,638 | 119,658 | |||||
FAQ
What was BioAtla's (BCAB) net loss for Q2 2024?
How much cash does BioAtla (BCAB) have as of June 30, 2024?
What is the FDA status of BioAtla's (BCAB) ozuriftamab vedotin for head and neck cancer?
When does BioAtla (BCAB) expect initial data from the evalstotug Phase 2 combination study?
